Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above

Herpes Zoster Clinical Trial

Official title:

A Phase II, Single Center, Randomized, Blind, Controlled Clinical Trial to Evaluate the Immunogenicity and Safety of Recombinant Herpes Zoster Vaccine (CHO Cells) in Healthy Subjects Aged 30 Years and Above

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05856084
• Other study ID #: MKKCT-100-002
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: May 7, 2023
• Est. completion date: March 31, 2026

Study information

• Verified date: October 2023
• Source: MAXVAX Biotechnology Limited Liability Company
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purposes of the study are to evaluate the immunogenicity and safety of different dose levels of recombinant herpes zoster vaccine (CHO Cells) with 2 doses at 2-month intervals in healthy subjects aged 30 years and older.

Description:

The clinical trial will be a single-center, randomized, blind, controlled study in which two dose levels of vaccine will be tested in healthy adults aged 30 to 49 years and 50 years and older. A total of 924 participants will be enrolled, including 396 participants aged 30 to 49 years and 528 participants aged 50 years and older. Participants aged 30 to 49 years will be randomized into three subgroups (low dose vaccine group, high dose vaccine group and placebo group) in a 1:1:1 ratio. Participants aged 50 years and older will be randomized into four subgroups (low dose vaccine group, high dose vaccine group, Shingrix® group and placebo group) in a 1:1:1:1 ratio.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 924
• Est. completion date: March 31, 2026
• Est. primary completion date: February 28, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

1. Permanent residents aged 30 years and above;

2. Subjects voluntarily agree to participate in the study and signed an informed consent;

3. Be able to participate in all scheduled visits and comply with the protocol requirements.

Exclusion Criteria:

1. Axillary temperature>37.0?;

2. History of herpes zoster within 5 years before vaccination;

3. Prior vaccination with chickenpox vaccine or herpes zoster vaccine;

4. Female participant who is pregnant ( urine pregnancy test was positive) or breastfeeding, or has pregnancy plans within 1 year after the last vaccination;

5. Receipt of live vaccine within 28 days, or any other vaccine within 14 days prior to vaccination;

6. Receipt of immunoglobulin or intravenous immunoglobulin within 3 months before vaccination;

7. Acute diseases or acute exacerbation of chronic disease within 3 days before vaccination;

8. A known allergy to any components of the study vaccine (especially allergic to aminoglycoside antibiotics), or history of severe allergy to any previous vaccination;

9. History of convulsions, epilepsy, encephalopathy (such as congenital brain dysplasia, brain trauma, brain tumor, cerebral hemorrhage, cerebral infarction, brain infection disease, nerve tissue damage caused by chemical drug poisoning, etc.) or mental illness and family history;

10. Asplenia or functional asplenia, or splenectomy caused by any condition;

11. Primary or secondary impairment of immune function or diagnosed congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus (SLE), rheumatoid arthritis, juvenile rheumatoid arthritis (JRA), inflammatory bowel disease or other autoimmune diseases;

12. Receipt of immunosuppressive therapy within 3 months before vaccination (such as long-term use of systemic glucocorticoid =14 days, dose =2mg/kg/day or =20mg/day prednisone or equivalent dose), but inhaled, intra-articular and topical steroids are acceptable;

13. Severe cardiovascular disease(eg. Pulmonary heart disease, Pulmonary Edema); Severe liver or kidney disease; or diabetes with complication;

14. History of thrombocytopenia or other coagulation disorders, which may cause intramuscular injection contraindications;

15. Abnormal blood pressure during physical examination before vaccination (systolic pressure = 140 mmHg and/or diastolic pressure = 90 mmHg);

16. Current or history of alcohol and/or drug abuse;

17. Any condition that, in the opinion the investigator, may affect the safety of the subject or the evaluation of the study results.

Related Conditions & MeSH terms

• Herpes Simplex
• Herpes Zoster

Intervention

Biological:
• Low dose Recombinant Herpes Zoster Vaccine (CHO cells)
0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with low dose MA105.
• High dose Recombinant Herpes Zoster Vaccine (CHO cells)
0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with high dose MA105.
• Positive control
0.5 mL per dose, containing a total of 50 µg recombinant varicella zoster virus glycoprotein E, adjuvanted with AS01B.
• Placebo
0.5 mL per dose, containing 4.5 mg sodium chloride.

Locations

Country	Name	City	State
China	Yanjin Center for Disease Control and Prevention	Xinxiang	Henan

Sponsors (2)

Lead Sponsor	Collaborator
MAXVAX Biotechnology Limited Liability Company	Henan Center for Disease Control and Prevention

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Geometric mean concentration (GMC) of anti-gE antibody	Measured by ELISA.	Month 1 after the last vaccination
Primary	Seropositivity rate of anti-gE antibody	The seropositivity rate is defined as the percentage of seropositive subjects. A seronegative subject is a subject whose antibody concentration is below the cut-off value. A seropositive subject is a subject whose antibody concentration is greater than or equal to the cut-off value.	Month 1 after the last vaccination
Primary	Seroresponse rate of anti-gE antibody	The seroresponse rate is defined as the percentage of subjects who have at least a: 4-fold increase in the antibody concentration as compared to the pre vaccination antibody concentration, for subjects who are seropositive at baseline, OR, 4-fold increase in the antibody concentration as compared to the antibody concentration cut-off value for seropositivity, for subjects who are seronegative at baseline.	Month 1 after the last vaccination
Primary	Geometric Mean Fold Rise (GMFR) of anti-gE antibody concentration	The antibody concentration at month 1 after the last vaccination compared with that at baseline (Day 0).	Month 1 after the last vaccination
Primary	Four-fold increase rate of anti-gE antibody concentration	The antibody concentration at month 1 after the last vaccination compared with that at baseline (Day 0).	Month 1 after the last vaccination
Primary	Cell-Mediated Immunity (CMI) response	CMI response is defined as the frequency of CD4+ T cells producing at least 2 activation markers (IFN-?, IL-2, TNF-a and/or CD40L) upon in vitro stimulation by gE peptide pools.	Month 1 after the last vaccination
Primary	Vaccine Response Rate (VRR)	VRR is defined as the percentage of participants with T-cell frequencies are =Cut-off value, for participants with T-cell frequencies	Month 1 after the last vaccination
Primary	The incidence and severity of adverse events	Incidence and severity of adverse events within 30 minutes after each vaccination. The severity of solicited and unsolicited adverse events will be graded from grade 1 to grade 4, other adverse events will be graded from grade 1 to grade 5.	Within 30 minutes after each vaccination
Primary	The incidence and severity of adverse events	Incidence and severity of adverse events within 7 days after each vaccination. The severity of solicited and unsolicited adverse events will be graded from grade 1 to grade 4, other adverse events will be graded from grade 1 to grade 5.	Within 7 days after each vaccination
Primary	The incidence and severity of adverse events	Incidence and severity of adverse events during Day 8 to 30 after each vaccination. The severity of solicited and unsolicited adverse events will be graded from grade 1 to grade 4, other adverse events will be graded from grade 1 to grade 5.	Day 8 to 30 after each vaccination
Primary	The incidence and severity of adverse events	Incidence and severity of adverse events within 30 days after each vaccination. The severity of solicited and unsolicited adverse events will be graded from grade 1 to grade 4, other adverse events will be graded from grade 1 to grade 5.	Within 30 days after each vaccination
Secondary	The incidence of Serious Adverse Events	Incidence of Serious Adverse Events (SAEs) from the first vaccination to 12 months after the last vaccination.	From the first vaccination to 12 months after the last vaccination
Secondary	Potential Immune-Mediated Diseases	Incidence of Potential Immune-Mediated Diseases (pIMDs) from the first vaccination to 12 months after the last vaccination.	From the first vaccination to 12 months after the last vaccination
Secondary	Geometric mean concentration (GMC) of anti-VZV antibody	measured by ELISA.	Month 1 after the last vaccination
Secondary	Seropositivity rate of anti-VZV antibody	The seropositivity rate is defined as the percentage of seropositive subjects. A seronegative subject is a subject whose antibody concentration is below the cut-off value. A seropositive subject is a subject whose antibody concentration is greater than or equal to the cut-off value.	Month 1 after the last vaccination
Secondary	Seroresponse rate of anti-VZV antibody	The seroresponse rate is defined as the percentage of subjects who have at least a: 4-fold increase in the antibody concentration as compared to the pre vaccination antibody concentration, for subjects who are seropositive at baseline, OR, 4-fold increase in the antibody concentration as compared to the antibody concentration cut-off value for seropositivity, for subjects who are seronegative at baseline.	Month 1 after the last vaccination
Secondary	Geometric Mean Fold Rise (GMFR) of anti-VZV antibody	The antibody concentration at month 1 after the last vaccination compared with that at baseline (Day 0).	Month 1 after the last vaccination
Secondary	Four-fold increase rate of anti-VZV antibody	The antibody concentration at month 1 after the last vaccination compared with that at baseline (Day 0).	Month 1 after the last vaccination
Secondary	Geometric mean concentration (GMC) of anti-gE antibody	measured by ELISA.	At 6, 12 and 24 months after the last vaccination
Secondary	Seropositivity rate of anti-gE antibody	The seropositivity rate is defined as the percentage of seropositive subjects. A seronegative subject is a subject whose antibody concentration is below the cut-off value. A seropositive subject is a subject whose antibody concentration is greater than or equal to the cut-off value.	At 6, 12 and 24 months after the last vaccination
Secondary	Geometric mean concentration (GMC) of anti-VZV antibody	measured by ELISA.	At 6, 12 and 24 months after the last vaccination
Secondary	Seropositivity rate of anti-VZV antibody	The seropositivity rate is defined as the percentage of seropositive subjects. A seronegative subject is a subject whose antibody concentration is below the cut-off value. A seropositive subject is a subject whose antibody concentration is greater than or equal to the cut-off value.	At 6, 12 and 24 months after the last vaccination
Secondary	Cell-Mediated Immunity (CMI) response	CMI response is defined as the frequency of CD4+ T cells producing at least 2 activation markers (IFN-?, IL 2, TNF-a and/or CD40L) upon in vitro stimulation by gE peptide pools.	At 6, 12 and 24 months after the last vaccination
Secondary	Vaccine Response Rate (VRR)	VRR is defined as the percentage of participants with T-cell frequencies are =Cut-off value, for participants with T-cell frequencies	At 6, 12 and 24 months after the last vaccination